First Eagle Investment Management LLC Has $5.85 Million Position in Maravai LifeSciences Holdings, Inc. $MRVI

First Eagle Investment Management LLC boosted its position in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) by 299.0% in the 4th quarter, HoldingsChannel.com reports. The firm owned 1,799,336 shares of the company’s stock after buying an additional 1,348,405 shares during the period. First Eagle Investment Management LLC’s holdings in Maravai LifeSciences were worth $5,848,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently modified their holdings of the company. Sprott Inc. bought a new stake in shares of Maravai LifeSciences in the third quarter valued at about $29,000. Quantessence Capital LLC bought a new position in Maravai LifeSciences during the third quarter worth about $31,000. Abel Hall LLC acquired a new stake in Maravai LifeSciences in the 3rd quarter worth about $33,000. CIBC Bancorp USA Inc. acquired a new stake in Maravai LifeSciences in the 3rd quarter worth about $33,000. Finally, Prudential Financial Inc. bought a new stake in Maravai LifeSciences in the 2nd quarter valued at about $36,000. Institutional investors and hedge funds own 50.25% of the company’s stock.

Wall Street Analysts Forecast Growth

MRVI has been the topic of a number of analyst reports. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $6.00 target price on shares of Maravai LifeSciences in a report on Friday, May 8th. Wells Fargo & Company boosted their price target on Maravai LifeSciences from $4.50 to $5.50 and gave the company an “overweight” rating in a research note on Friday, May 8th. Finally, Wall Street Zen upgraded Maravai LifeSciences from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $5.50.

Maravai LifeSciences Stock Down 6.2%

Shares of MRVI opened at $4.37 on Thursday. The company has a debt-to-equity ratio of 0.72, a quick ratio of 5.69 and a current ratio of 5.91. The stock has a market capitalization of $1.12 billion, a price-to-earnings ratio of -6.15 and a beta of 0.62. Maravai LifeSciences Holdings, Inc. has a 52 week low of $1.95 and a 52 week high of $4.99. The stock has a fifty day moving average of $3.43 and a 200-day moving average of $3.43.

Maravai LifeSciences (NASDAQ:MRVI) last announced its quarterly earnings results on Thursday, May 7th. The company reported $0.01 EPS for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.06. Maravai LifeSciences had a negative return on equity of 17.87% and a negative net margin of 51.07%.The firm had revenue of $65.84 million for the quarter, compared to analyst estimates of $53.00 million. As a group, sell-side analysts anticipate that Maravai LifeSciences Holdings, Inc. will post -0.26 earnings per share for the current fiscal year.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.